NASDAQCHRS

In: Finance

phototechno Canadian drug developer Apotex on Tuesday announced an agreement with Coherus Biosciences (NASDAQ:CHRS) to buy Canadian rights to the former’s cancer therapy toripalimab, marketed in the U.S. as Loqtorzi for head and neck cancer. Under the agreement, Apotex will hold exclusive Canadian rights to toripalimab, an anti-PD-1 monoclonal antibodyContinue Reading

In: Finance

Eoneren Coherus BioSciences (NASDAQ:CHRS) announced on Thursday that it would receive $40M in cash upfront as part of an agreement to divest its biosimilar therapy Yusimry targeted at AbbVie’s (ABBV) blockbuster arthritis therapy Humira. The deal with Chinese drugmaker Hong Kong King-Friend Industrial Co. Ltd. closed on June 26, 2024,Continue Reading